Laurus Labs surges 50% in one month on growth prospects in US market

The stock hit a 52-week high of Rs 494, up 9 per cent on the BSE on Wednesday, surging 20 per cent in past two trading days on expectation of strong growth prospects in United States.

Shares of Laurus Labs hit a 52-week high of Rs 494, up 9 per cent on the BSE on Wednesday, surging 20 per cent in the past two trading days on expectation of strong growth prospects in the United States (US). In the past one month, the stock of Laurus Labs has rallied 50 per cent, as compared to a 3 per cent rise in the S&P BSE Sensex.

Laurus Labs on March 27 said it will supply anti-malarial drug Hydroxychloroquine to its US partner Rising Pharma Holdings to test as a preventive treatment for novel coronavirus, or COVID-19.